These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 25488385)

  • 1. Commentary on "Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle." Mertens LS, Fioole-Bruining A, Vegt E, Vogel WV, van Rhijn BW, Horenblas S, Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam Hospital, Amsterdam, The Netherlands.: BJU Int 2013; 112(6):72934. doi:10.1111/bju.12109. [Epub 2013 Jun 24].
    See WA
    Urol Oncol; 2014 Nov; 32(8):1350. PubMed ID: 25488385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorodeoxyglucose positron-emission tomography (FDG PET)/computed tomography (CT) in bladder cancer.
    Goh V; Cook G
    BJU Int; 2013 Oct; 112(6):709. PubMed ID: 24028759
    [No Abstract]   [Full Text] [Related]  

  • 4. Diuretic 18F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: prospective evaluation of a novel technique.
    Nayak B; Dogra PN; Naswa N; Kumar R
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):386-93. PubMed ID: 23179944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Staging
    Voskuilen CS; van Gennep EJ; Einerhand SMH; Vegt E; Donswijk ML; Bruining A; van der Poel HG; Horenblas S; Hendricksen K; van Rhijn BWG; Mertens LS
    Eur Urol Oncol; 2022 Jun; 5(3):366-369. PubMed ID: 33583752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [(18)F]Fluorodeoxyglucose - positron emission tomography/computed tomography improves staging in patients with high-risk muscle-invasive bladder cancer scheduled for radical cystectomy.
    Kollberg P; Almquist H; Bläckberg M; Cronberg C; Garpered S; Gudjonsson S; Kleist J; Lyttkens K; Patschan O; Liedberg F
    Scand J Urol; 2015; 49(4):296-301. PubMed ID: 25623843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
    Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
    Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer.
    Goodfellow H; Viney Z; Hughes P; Rankin S; Rottenberg G; Hughes S; Evison F; Dasgupta P; O'Brien T; Khan MS
    BJU Int; 2014 Sep; 114(3):389-95. PubMed ID: 24341486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer.
    Mertens LS; Mir MC; Scott AM; Lee ST; Fioole-Bruining A; Vegt E; Vogel WV; Manecksha R; Bolton D; Davis ID; Horenblas S; van Rhijn BW; Lawrentschuk N
    Urology; 2014 Feb; 83(2):393-8. PubMed ID: 24468513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Staging fluorodeoxyglucose positron emission tomography/computed tomography for muscle-invasive bladder cancer: a nationwide population-based study.
    Richters A; van Ginkel N; Meijer RP; Wondergem M; Schoots I; Vis AN; Kiemeney LALM; van Rhijn BWG; Witjes JA; Aben KKH; Mertens LS
    BJU Int; 2023 Oct; 132(4):420-427. PubMed ID: 37246479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential impact of 18F-FDG PET/CT on patients selection for neoadjuvant chemotherapy before radical cystectomy.
    Rouanne M; Girma A; Neuzillet Y; Vilain D; Radulescu C; Letang N; Yonneau L; Hervé JM; Botto H; Le Stanc E; Lebret T
    Eur J Surg Oncol; 2014 Dec; 40(12):1724-30. PubMed ID: 25242381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study.
    Zattoni F; Incerti E; Colicchia M; Castellucci P; Panareo S; Picchio M; Fallanca F; Briganti A; Moschini M; Gallina A; Karnes JR; Lowe V; Fanti S; Schiavina R; Rambaldi I; Ficarra V; Evangelista L
    Abdom Radiol (NY); 2018 Sep; 43(9):2391-2399. PubMed ID: 29302738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging.
    Groheux D; Giacchetti S; Delord M; Hindié E; Vercellino L; Cuvier C; Toubert ME; Merlet P; Hennequin C; Espié M
    J Nucl Med; 2013 Jan; 54(1):5-11. PubMed ID: 23213197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma.
    Kibel AS; Dehdashti F; Katz MD; Klim AP; Grubb RL; Humphrey PA; Siegel C; Cao D; Gao F; Siegel BA
    J Clin Oncol; 2009 Sep; 27(26):4314-20. PubMed ID: 19652070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
    van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
    J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorodeoxyglucose positron emission tomography (18F-FDG PET)-computed tomography (CT) in the initial staging of bladder cancer: a single institution experience.
    Shahait M; Abu-Hijlih R; Farkouh A; Obeidat S; Salah S; Abdlkadir AS; Al-Ibraheem A
    J Egypt Natl Canc Inst; 2023 Jul; 35(1):21. PubMed ID: 37455263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG PET-CT for lymph node staging of bladder cancer: a prospective study of patients with extended pelvic lymphadenectomy.
    Jeong IG; Hong S; You D; Hong JH; Ahn H; Kim CS
    Ann Surg Oncol; 2015 Sep; 22(9):3150-6. PubMed ID: 25634779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Diagnostic Value of FDG-PET/CT for Urachal Cancer.
    Stokkel LE; Stokkel MPM; Donswijk ML; Lahaye MJ; Bekers EM; van Rhijn BWG; Mertens LS
    Clin Genitourin Cancer; 2021 Oct; 19(5):373-380. PubMed ID: 33858788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of (18)F-FDG PET-CT in staging and restaging of patients with malignant salivary gland tumours: a single-institutional experience.
    Sharma P; Jain TK; Singh H; Suman SK; Faizi NA; Kumar R; Bal C; Malhotra A; Kumar R
    Nucl Med Commun; 2013 Mar; 34(3):211-9. PubMed ID: 23353886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma.
    Jadvar H; Quan V; Henderson RW; Conti PS
    Int J Clin Oncol; 2008 Feb; 13(1):42-7. PubMed ID: 18307018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.